P Labauge
Overview
Explore the profile of P Labauge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
1571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farge D, Pugnet G, Allez M, Castilla-Llorente C, Chatelus E, Cintas P, et al.
Rev Med Interne
. 2024 Jan;
45(2):79-99.
PMID: 38220493
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc)...
2.
Ciron J, Gueguen A, Al Khedr A, Bourre B, Clavelou P, Defer G, et al.
Rev Neurol (Paris)
. 2022 Sep;
178(10):1098-1104.
PMID: 36180289
Background: In clinical practice, the diagnosis of secondary progressive multiple sclerosis (SPMS) is often delayed, retrospective and non-reproducible, as there are no consensus criteria that define the advent of SPMS....
3.
Grangeon L, Quesney G, Verdalle-Cazes M, Coulette S, Renard D, Wacongne A, et al.
J Neurol
. 2022 Jun;
269(9):4972-4984.
PMID: 35752990
Objective: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare manifestation related to CAA, thought to be more severe. We aimed to compare the clinical and radiological outcomes of CAA-ri and...
4.
Lefort M, Sharmin S, Andersen J, Vukusic S, Casey R, Debouverie M, et al.
BMC Med Res Methodol
. 2022 May;
22(1):155.
PMID: 35637426
Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment...
5.
Bouleau A, Dulong C, Schwerer C, Delgrange R, Bouaou K, Brochu T, et al.
Mult Scler J Exp Transl Clin
. 2022 Apr;
8(2):20552173221093219.
PMID: 35479962
Background: Multiple sclerosis (MS) places a considerable financial burden on the society. However, data quantifying the contemporary cost burden in France are lacking. Objective: This cost-of-illness study aimed to estimate...
6.
Ayrignac X, Zagroun C, Coget A, Azakri S, Menjot de Champfleur N, Montcriol A, et al.
Eur J Neurol
. 2020 Aug;
27(12):2517-2522.
PMID: 32810911
Background And Purpose: The purpose was to evaluate, in a consecutive series of patients with isolated acute retinal ischaemia, the proportion of patients with acute silent brain infarcts (SBIs) on...
7.
Ayrignac X, Gaillard N, Carra-Dalliere C, Labauge P
Rev Med Interne
. 2020 Jul;
41(7):469-474.
PMID: 32718708
Small vessel disease of the brain is commonly identified among ageing people. It causes almost 25% of strokes and is associated with cognitive impairment and dementia as well as gait...
8.
Labauge P
Rev Neurol (Paris)
. 2020 Apr;
176(6):494-496.
PMID: 32334842
RR MS evolution has changed since the beginning of the availability of MS disease-modifying drugs (DMD). Before concluding a unique impact of the efficiency of DMD, careful analysis of long-term...
9.
Ayrignac X, Carra-Dalliere C, Labauge P
Rev Neurol (Paris)
. 2020 Apr;
176(9):739-749.
PMID: 32312496
Inflammatory diseases of the central nervous system (CNS) mainly occur during early adulthood and multiple sclerosis (MS) represents the overwhelming majority of these disorders. Nevertheless, MS only rarely begins after...
10.
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, et al.
Mult Scler
. 2020 Feb;
27(2):232-238.
PMID: 32077365
Background: Atypical myelitis in multiple sclerosis (MS) is characterized by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis). Objective: To characterize a cohort of...